Rabbit Polyclonal DGAT1 antibody. Suitable for WB and reacts with Human samples. Cited in 25 publications. Immunogen corresponding to Synthetic Peptide within Human DGAT1.
View Alternative Names
AGRP1, DGAT, DGAT1, Diacylglycerol O-acyltransferase 1, ACAT-related gene product 1, Acyl-CoA retinol O-fatty-acyltransferase, Diglyceride acyltransferase, ARAT, Retinol O-fatty-acyltransferase
- WB
Unknown
Western blot - Anti-DGAT1 antibody (AB54037)
All lanes:
Western blot - Anti-DGAT1 antibody (ab54037) at 2 µg/mL
All lanes:
HepG2 lysate
Predicted band size: 55 kDa
Observed band size: 55 kDa
false
- WB
CiteAb
Western blot - Anti-DGAT1 antibody (AB54037)
Western Blotting using Anti-DGAT1 antibody, ab54037. Publication image from Corbet, C. et al., 2020, Nat Commun, 31974393. Legend direct from paper.
TGF-β2 promotes FA uptake and TG accumulation into LD.a–c Abundance of neutral lipids (NL), phospholipids (PL) and free fatty acids (FFA) (a), abundance of saturated and monounsaturated fatty acids (SFA and MUFA, respectively) in the neutral lipid fraction (b), and LD content (c) in native SiHa cells after treatment with 4 ng/ml TGF-β2 for 6 h. d, e14C-palmitate uptake for 10 min in SiHa cells after treatment with 4 ng/ml TGF-β2 for 6 h (d) and in acidosis-adapted SiHa cells following treatment with 10 µM Trabedersen for 7 days in absence or presence of 4 ng/ml TGF-β2 for 24 h (e). f–h Representative immunoblotting for cell surface-localized CD36 and total biotinylated proteins in native and acidosis-adapted SiHa cells following treatment with 4 ng/ml TGF-β2 for 6 h and 24 h (f), following treatment with 10 µM Trabedersen for 7 days or 2 µM SB431542 for 24 h (g) or with 4 ng/ml TGF-β2 and 10 µM PKC-ζ pseudo-substrate inhibitor for 24 h (h). i, j Quantification of surface-localized CD36 in native and acidosis-adapted SiHa cells treated as indicated in (h). k, l mRNA (k) and protein expression of DGAT1 (l) in native and acidosis-adapted tumor cells. m–o Representative immunoblotting for DGAT1 in native and acidosis-adapted SiHa cells following treatment with 10 µM Trabedersen for 7 days or 2 µM SB431542 for 24 h (m), with 10 µM PKC-ζ pseudo-substrate inhibitor for 24 h (n) or with 10 µM GW6471 for 48 h (o). p mRNA expression of PLIN2 in native and acidosis-adapted SiHa cells following treatment with 10 µM TGFβ2-specific antisense oligonucleotide Trabedersen for 7 days. q Co-expression analysis of TGFB2, PLIN1, PLIN2, and PLIN3 genes in human healthy volunteers and colorectal cancer patient samples. Data are represented as mean ± SEM of three independent experiments (with ≥6 technical replicates). Significance was determined by Student’s t-test (c, d, j), by one-way ANOVA (e–i) or two-way ANOVA (a, k, p) with Bonferroni multiple-comparison analysis. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. Source data are provided as a Source Data file.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
DGAT1 plays a significant role in lipid homeostasis and energy balance across multiple biological systems. This enzyme is key in the conversion of dietary fats into stored energy and it does not exist as part of a complex. DGAT1's activity contributes to the maintenance of cellular lipid droplets and it has implications therefore in conditions where lipid metabolism is disrupted.
Pathways
DGAT1 is a part of the triglyceride biosynthesis pathway an important route within the lipid metabolism framework. In this context the enzyme works alongside other lipogenic proteins such as acetyl-CoA carboxylase and fatty acid synthase to synthesize triglycerides. DGAT1's role in this pathway has implications for how the body manages fat storage and utilization linking it to the regulation of systemic energy levels.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (25)
Recent publications for all applications. Explore the full list and refine your search
Journal of cardiovascular translational research : PubMed39384702
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of animal science and biotechnology 15:105 PubMed39098913
2024
Applications
Unspecified application
Species
Unspecified reactive species
Physiological reports 11:e15608 PubMed36802195
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports 39:110995 PubMed35732120
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell metabolism 33:1701-1715.e5 PubMed34118189
2021
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 11:914 PubMed33099578
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cells 9: PubMed32977490
2020
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of nutritional biochemistry 80:108364 PubMed32199344
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 11:454 PubMed31974393
2020
Applications
Unspecified application
Species
Unspecified reactive species
Diabetes & metabolism journal 43:683-699 PubMed31694081
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com